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Abstract
Background: Osteosarcoma is the most common primary tumour of bone. Solid tumours are made of heterogeneous cell
populations, which display different goals and roles in tumour economy. A rather small cell subset can hold or acquire stem
potentials, gaining aggressiveness and increasing expectancy of recurrence. The CD133 antigen is a pentaspan membrane
glycoprotein, which has been proposed as a cancer stem cell marker, since it has been previously demonstrated to be
capable of identifying a cancer initiating subpopulation in brain, colon, melanoma and other solid tumours. Therefore, our
aim was to observe the possible presence of cells expressing the CD133 antigen within solid tumour cell lines of
osteosarcoma and, then, understand their biological characteristics and performances.
Methodology and Principal Findings: In this study, using SAOS2, MG63 and U2OS, three human sarcoma cell lines isolated
from young Caucasian subjects, we were able to identify and characterize, among them, CD133
+ cells showing the following
features: high proliferation rate, cell cycle detection in a G2\M phase, positivity for Ki-67, and expression of ABCG2
transporters. In addition, at the FACS, we were able to observe the CD133
+ cell fraction showing side population profile and
forming sphere-clusters in serum-free medium with a high clonogenic efficiency.
Conclusions: Taken together, our findings lead to the thought that we can assume that we have identified, for the first time,
CD133
+ cells within osteosarcoma cell lines, showing many features of cancer stem cells. This can be of rather interest in
order to design new therapies against the bone cancer.
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Introduction
Osteosarcoma is the most common primary tumour of bone. It
occurs in bone and extra osseous sites, and displays a bimodal age
distribution, with a first peak during the second decade of life,
related to the adolescent growth spurt (400 new paediatric cases
per year in the Unites States) and a second peak in older adults [1].
The incidence is slightly higher in African-Americans than in
Caucasians and death is usually the result of progressive
pulmonary metastasis with respiratory failure due to widespread
disease [2]. Sarcoma genetic alterations include both oncosup-
pressor and oncogene pathways, whose products regulate cell cycle
progression [3]. Actually, it is well known that solid tumours are
populated by heterogeneous cell populations that include cells with
stem-like properties, such as high proliferation rate, quick
expansion and invasive growth [4,5].
A tumour can be envisaged as a whole organ, formed by different
cells displaying distinct roles in the economy of the tumour. It is well
knownthatthefunctionofstemcellsistomaintainandrepairtissues.
Stem potential can be also acquired by cancerous cell and this event
is very important for tumour progression.
Current opinion is that tumours may derive from a small
number of cells having stem-like characteristics. New therapies
targeting these cells, which are fundamental for tumor progression,
could significantly improve clinical treatment of cancer. Therefore,
it is of paramount importance to identify, within tumours,
subpopulations of cells exhibiting significant differences in terms
of proliferation, stem marker expression and behaviour.
The CD133 antigen is a pentaspan membrane glycoprotein,
characterized by two independent studies [6,7] and originally
identified in neuroepithelial stem cells [8]. Its interest as a cancer
stem marker has grown dramatically since it appeared that it was
able to identify a cancer initiating subpopulation in brain [9] and
colon [10]. Moreover, CD133
+ cells have also been found in
hepatocarcinoma [11] and melanoma [12] but, up to now, not yet
in osteosarcomas, in which the presence of supposed stem-like cells
forming spheres has been reported [13].
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3469Therefore, we aimed to use the CD133 as a marker to detect the
possible presence of cancer stem cells within SAOS2, MG63 and
U2OS human sarcoma cell lines isolated from osteosarcomas of
young Caucasian subjects. These cell lines have been previously
used as models of osteosarcoma [14,15] and osteoblast-like
cells [16,17]. In this study, in order to specifically identify
CD133
+ cancer stem cells, we have investigated the relationship
between stem features and the kinetics of the CD133 marker
expression.
Our results, first of all demonstrate, for the first time, that the
CD133 antigen is observable in cells in different osteosarcoma
stabilized cell lines. Moreover, we have shown that these cells
display high proliferation rate and that they are capable of forming
cluster spheres. In addition, we have found that these cells are
highly clonogenic and tumorigenic. Taken together, our data lead
to the thought that cancer stem cells (CSCs), that are tumour
initiating cells, can be found in osteosarcomas and this may be of
paramount importance when designing new anti-cancer therapies
for bone.
Results
SAOS2, U2OS and MG-63 osteosarcoma cell lines were tested
in order to detect, within them, the presence of a CD133
+ cell
population. CD133 is a stem cell marker described for the first
time in neuro-endothelial progenitors, and recently has been
supposed to be a selective marker for Cancer Stem Cells (CSC) in
some cancer types. Our results clearly show that in all of the three
cells lines, two subpopulations: a CD133
+ (ranging from 3% to
5%) and a CD133
2, can be identified (Fig. 1). Using the
FACsorting, we obtained a CD133
+ enriched population
(98.8%) and a CD133
2 cell population. The expression of the
CD133 antigen was analyzed by using two different antibodies.
Results confirmed that the CD133 negative cells did not express
the antigen on the cell surface and that the CD133 positive cells
were expressed at the same percentage level using both antibodies.
Besides, all the three cell lines were negative for CD34 antigen
but they evidenced equal strong positivity for CD29, CD44 and
CD90, mesenchymal and cancer stem cells markers. Both the
fractions of CD133
+ and CD133
2 cells were positive for CD29,
CD44 and CD90 antigens in all three cell lines (Fig. 2).
The two cell populations (CD133
+ and CD133
2) were then
used to perform cell cycle analysis, growth analysis, sphere cluster
formation assay, soft agar assay and side population detection.
Cell cycle, Proliferation assays and Growth analyses
Propidium Iodide (PI) assay showed a marked difference in the
cell cycle of CD133 sorted cells. CD133
+ cells were mostly in the
G2\M phase, while CD133
2 cells were predominantly in G0\G1
(Fig. 3A), indicating that the CD133
+ subpopulation is the active
proliferating cell fraction. Moreover, all the CD133
+ cells resulted
to be Ki-67
+ (Fig. 3B) while the majority of CD133
2 cells were
negative for this marker. Ki-67 is a protein expressed only in
proliferating cells, thus our results confirm that the CD133
+
fraction is the source of newly generated cells.
In addition, in order to show whether CD133
+ cells were
capable of extensivelly proliferate when compared to CD133
2
cells, we observed their growth. Our data showed that the tumour
cultures derived from CD133
+ cells display higher proliferative
potential with respect to CD133
2 cells in all the three cell lines. In
fact (Fig 3C) CD133
+ cells exhibited a mean doubling time of
approximately 40 h, 33 h and 38 h in SAOS2, MG63 and U2OS
cell lines respectively, whereas CD133
2 cells showed a mean
doubling time of 48 h, 44 h and 42 h in SAOS2, MG63 and
U2OS cell lines respectively. When cells were adherent, after
sorting, the percentage of CD133 expressing cells significantly
decreased (p,0.001) with time of culture (data not shown).
Figure 1. Cytometric analyses for CD133 on SAOS2, MG63 and U2OS cell lines. A CD133
+ cell population can be detected in all the three
cell lines.
doi:10.1371/journal.pone.0003469.g001
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The ability to grow in suspension in serum free medium,
described for the first time to select neural stem cell through
neurosphere formation, has been largely investigated as a tumor
initiating cell selection method. Glioblastoma, colon cancer, and
melanoma cells above all, selected for their ability to form sphere
clusters, were found to be highly tumorigenic and able to
propagate and reconstitute original tumor architecture when
injected into permissive hosts. Our results on osteosarcoma cell
lines indicated that sphere clusters were clearly observed already
after 24 h in CD133
+ cultures (Fig. 4A,C,D), while CD133
2 did
not form spheres (Fig. 4B). After 7 days of culture, spheres
obtained in CD133
+ cells were seeded in standard plates with 10%
FBS. Cells migrated from the spheres within a few hours and
adhered to the bottom of the flasks, assuming a polygonal shape.
These cells resulted to be smaller in size, compared with CD133
2
cells. After a week, we performed an additional test for the CD133
antigen on adherent cells. Interestingly, again a CD133
2
population was observed, providing evidence that CD133
2 cells,
at this time, derive from CD133
+ cell. Then, we performed a new
sorting of these cells and observed that the CD133
+ fraction still
retained the ability to form spheres, while the CD133
2 did not.
In addition we tested OCT3/4 and CD133 expressions at 6
th
cell passage and at 4
th and 6
th passage, respectively on sarco-
spheres derived from CD133
+ cells after sorting. Results showed
that the spheres were enriched both in OCT3/4 and CD133 with
time of culture (Fig. 5).
Soft Agar Assay
Soft agar assays were performed in order to observe differences in
cell tumorigenicity by means of the ability of CD133
+ cells to form
colonies with respect CD133
2 cells. As shown in Table 1, colonies
were formed more efficiently by CD133
+ cells, which gave rise to a
5.561.8-fold larger number of colonies than those detected in
CD133
2 population (p,0.005) in SAOS2; 7.761.5-fold larger
number of colonies than those observed in CD133
2 population
(p,0.001) in MG63, and 6.861.7-fold larger number of colonies
than those observed in CD133
2 population in U2OS (P,0.005).
Side population and ABCG2
Within the CD133
+ fraction a very small subset (0.97%)
expressed the characteristic profile of a side population. It is
known that the side population phenotype is the most significant
attribute of cancer stem cells. In this study we show for the first
time that in osteosarcoma cell lines a side population can be
detected. Moreover, we found that all the three cell lines expressed
the ABCG2 transporter (Fig. 6) which are usually associated with
side population phenotype and drug resistance.
Immunohistochemistry and immunofluorescence
Both immunohistochemical and immunofluorescence analyses
on adhered cells and floating spheres were performed in this study.
Our results, accordingly with FACS analyses, confirmed the
presence of the CD133 antigen on the cell membrane of CD133
+
sorted cells. Moreover, floating spheres showed a widely diffuse
staining for CD133, corroborating the fact that spheres are formed
by CD133
+ cells. Interestingly, the CD133
2 sorted fraction were
stained for CD133, that was localized within intra-cytoplasmic
vesicles as shown at confoal microscopy (Fig. 7A,B,C,D,E,F). In
order to deeply understand this aspect, we performed, at the
FACS, an intra-cellular staining for CD133. We found that in all
of the three cell lines an intracellular positivity was observed
(Fig. 8A), while control isotypes were negative.
Real Time-PCR analysis
The expression of CD133 mRNA levels in CD133
+ and
CD133
2 adherent cells were almost identical as detected by Real
Time PCR (Fig. 8B). This confirms both FACS and immunoflu-
orescence results, as shown above.
Discussion
Osteosarcoma is a highly aggressive tumour, which prevailingly
affects young people. Following recent studies [10–13,18]
supporting the presence of a highly tumorigenic cell subset –
commonly called Cancer Stem Cells (CSCs) – within the tumour
bulk, we tried to isolate and characterize this subpopulation in
osteosarcoma cell lines. Tumour lesions encompass heterogeneous
cell populations, among which the presence of stem antigens can
be evidenced by means of phenotypical analyses. The presence of
a CD133
+ subpopulation within human solid tumours has been
documented by several reports [10–13,18–21], and cells express-
ing this marker seem to be different from the other cancerous cells.
In particular, CD133
+ cells possess stem-like features, such as
differentiation ability, high proliferation rate, sphere cluster
formation and the ability to propagate tumour in permissive
hosts. Cancer therapy failures may be due to inefficient effects of
current therapy upon potentially quiescent CSCs, which remain
vital and retain the capacity to regenerate the tumour [22,23].
Development of new CSC-targeted strategies is currently hindered
by the lack of reliable markers for the identification of CSCs and
the poor understanding of their behaviour and fate. Cell lines,
derived from tumours, retain hierarchical stem cell patterns,
demonstrable with different clonogenic abilities, related to cellular
properties, such as size, adhesiveness, dye exclusion and gene
expression patterns [24].
In this study, we used the CD133 antigen as a cancer stem-cell
marker in order to identify, within stabilized osteosarcoma cell lines,
cells exhibiting different properties in terms of proliferation rate,
clonogenic efficiency, sphere-cluster formation and dye exclusion.
Screening three osteosarcoma cell lines, CD133
+ subsets were found
to be 3% to 5% of total cells, according with the assumption that
CSCsshouldbeonlyaverysmallcellsubset.Therearenodifferences
in the CD29, CD44 and CD90 expressions both in CD133
+ and
CD133
2 cells. Actually, cancer stem cells are considered to be
quiescent in vivo and they rarely divide asymmetrically, giving birth to
highly proliferating progeny [5]. Nevertheless, if a stem hierarchy
does exist in cell lines, cells with stem features cannot be quiescent;
otherwise, they should be lost in a few passages. According with this
consideration, we found that CD133
+ cells were highly proliferative,
when compared with CD133
2 cells, as confirmed by PI analysis, Ki-
67 labelling and growth analyses.
CD133
+ cells showed many differences with respect to their
negative counterparts, having the ability to grow as spheres in a
semisolid medium and to efficiently form colonies in soft agar.
These assays are commonly regarded respectively as indexes of
self-renewal, tumorigenicity and clonogenicity. Moreover, sarco-
spheres, which derived from CD133
+cells, expressed high levels of
OCT3/4, that are transcription factors critically involved in self-
renewal and in the maintenance of pluripotency of undifferenti-
ated embryonic stem cells [25]. In our hands the CD133
+ cells
showed all those abilities and expressed ABCG2, which is a
membrane transporter, usually associated with side population
phenotype and drugs resistance [26]. Therefore, this can be
considered to be an additional marker for CSCs. In addition, in
this study, we effectively showed, for the first time, that a side
population can be detected also in osteosarcoma cell lines. The
side population is defined by Hoechst exclusion in flow cytometry
CD133 in Solid Tumours
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negative for CD34 antigen but they evidence equal strong positivity for CD29, CD44 and CD90.
doi:10.1371/journal.pone.0003469.g002
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population and expresses high levels of various members of the
ABC transporter family , such as ABCG2 and MDR1, which are
responsible for drug resistance [29,30]. As expected, we found that
the side population was made by a very small fraction (0.97%) of
the total cells, and, interestingly, it was completely included within
the CD133
+ subset.
Our data, taken together, may lead to the tought that CD133
+
cells are cancer stem cells. Actually, although this should be
supported by an in vivo tumour xenograft, as shown in other solid
tumours [10–13,18–21], unfortunately, we were not able to
perform in vivo experiments because osteosarcoma cell lines do not
graft with any host. We effectively tried to perform in vivo
transplantation of our CD133 stem cells, but without success, like
all the others researchers.
In addition, we may also hypothesize that the CD133
+ subset
encompasses a smaller CD133
+\ABCG2
+\SP
+ population, which
could be resistant to drugs, possesses stem features and may
effectively drives cancer progression.
Interestingly and unexpectedly, in our hands, some cells that did
not express the CD133 marker on the membrane resulted to
produce a detectable amount of CD133 mRNA transcripts, and
expressed the CD133 antigen in cytoplasmic vesicles as shown by
confocal microscopy. Nevertheless, CD133
+ and CD133
2 sorted
populations clearly display different behaviours. This leads us to
speculate on the functional role of CD133 in organizing the
membrane and in selecting CSCs, as follows: i) being CD133
highly involved in sphere cluster formation, it is necessary for non-
adherent cell growth as well as for cell-to-cell cross talk, which
allows cells to communicate and receive stimuli that are normally
supplied by adhesion molecules; ii) CD133
+ and CD133
2
populations are in continuous and mutual exchange and only
true CSCs express CD133 constantly on the membrane.
In conclusion, our findings suggest that CD133 marker may be
useful to indicate the differentiated/undifferentiated state of
osteosarcoma tumours and this may lead to new approaches in
order to design a more specific therapy and ameliorate prognosis.
Materials and Methods
Cell culture
SAOS2, MG63 and U2OS were purchased from ATCC CELL
BANK; cells were placed in a-MEM culture medium, supple-
mented with 15% FCS, 100 mM 2P-ascorbic acid, 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (all
purchased from Invitrogen, San Giuliano Milanese, Milan, Italy)
and placed in 75 ml flasks with filtered valves. Flasks were
incubated at 37uC in a 5% CO2 and the medium changed twice a
week. After confluence, cells were subdivided into new flasks until
the end of the experiment.
Flow Cytometry and Cell Sorting
Cells were detached using 0.02% EDTA in phosphate-buffered
saline (PBS), counted and washed in 0.1% BSA in PBS. At least
500,000 cells (in 100 ml PBS/0.5% BSA) were incubated with
fluorescent-labelled monoclonal antibodies or respective isotype
controls (1/10 diluted 4uC for 30 min in the dark). After washing
steps, the labelled cells were analyzed by flow cytometry using a
Figure 3. Cell cycle, proliferation and growth analyses. (A) Figure of cell cycle analyses performed on SAOS2, MG63 and U2OS cell lines. A
CD133
+ cell population is mainly observable in the G2\M phase, whereas CD133
2 cells were predominantly in G0\G1; (B) Figure showing Ki-67
reactivity. CD133
+ cells resulted to be Ki-67
+, whereas CD133
2 were mainly negative for this marker; (C) Figure showing growth curves of CD133
+
cells with respect CD133
2 cells in SAOS2, MG63 and U2OS cell lines. CD133
+ cells possess a high proliferative potential in all the three cell lines.
doi:10.1371/journal.pone.0003469.g003
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CA,USA). The antibodies used were mouse anti-human CD133/2
PE conjugated (Miltenyi Biotec S.r.l. Calderara di Reno, Bologna,
Italy), mouse anti-human CD133 PE conjugated (eBioscience),
mouse anti-human CD29 CY conjugated (BD Pharmingen,Bucci-
nasco,Milan, Italy), mouse anti-human CD34 PE conjugated
(Miltenyi Biotec), mouse anti-human CD44 FITC conjugated
(Miltenyi Biotec), mouse anti-human CD90 FITC conjugated (BD
Pharmingen), mouse anti-human OCT3/4 non conjugated (Santa
Cruz Biotechnology, Inc. Santa Cruz, California, U.S.A), mouse
Figure 4. Spheres assay. (A) Sphere clusters formed by CD133
+ cells in semisolid medium after 24 hours (Original Magnification 6100); (B)
CD133
2 cells in semisolid medium after 7 days, do not form spheres. (Original Magnification6100); (C) Sphere clusters formed by CD133
+ cells after
48 hours (Original Magnification 6200); (D) Sphere clusters formed by CD133
+ cells after a new sorting (Original Magnification 6400).
doi:10.1371/journal.pone.0003469.g004
Figure 5. Cytometric analyses for CD133 and OCT3/4 on sarcospheres in SAOS2, MG63 and U2OS. The blue line indicates isotype
controls, red and green lines indicate the expression of CD133 at the 4
th and 6
th cell passage, respectively. In the histograms, OCT3/4 expression is
analyzed at the 6
th cell passage; the green line indicates isotype controls. Sarcospheres both in CD133 and OCT3/4 are strongly positive.
doi:10.1371/journal.pone.0003469.g005
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anti-human ABCG2 non conjugated (Santa Cruz). CD133
+ cells
were sorted for experiments. CD133
2 cells were harvested as
control. The purity of sorted populations was routinely 90%.
Isotypes were used as controls.
Seven days after sorting, CD133
2 cells were detached and
tested twice for CD133 expression. OCT3/4 expression was
analysed at 6
th cell passage (a ‘‘passage’’ indicates that cells are
detached when at confluence) whereas CD133 expression was
analysed at 4
th and 6
th cell passage on sarcopheres derived from
CD133
+ cells in the three cell lines.
For intracellular staining of Ki67, CD133 and OCT3/4, cells
were processed using the Caltag Fix & Perm Kit (Invitrogen,
Milan, Italy) following the manufacturer’s guidelines. All data were
analyzed using a CellQuest software.
Hoechst 33342 Exclusion Assay
SAOS2, MG63 and U2OS cells were resuspended at
2.0610
6 cells/ml in pre-warmed a-MEM culture medium and
divided into two portions. A portion was treated with 50 mM
verapamil and the other was left untreated. Both portions were
incubated in a-MEM culture medium with 5 mg/ml Hoechst
33342 (Sigma, Milan, Italy) for 90 minutes at 37uC. After
incubation the cells were washed in PBS and kept on ice for
5 minutes, and analyzed for Hoechst 33342 efflux by FACS
vantage (Becton Dickinson, Milan, Italy) [31]. The Hoechst 33342
dye was excited at 350 nm ultraviolet and resultant fluorescence
was measured at two wavelengths using a 424/44 BP and 675 LP
filters for detection of Hoechst blue and red, respectively.
Cell Cycle and Proliferation Analyses
Cell cycle was analysed by flow cytometry. Cells were harvested
in PBS containing 2 mM EDTA, washed once with PBS, fixed in
iced ethanol 70u and incubated with 50mg/ml PI (Sigma) plus
Rnasi 1 mg/ml for 60 min at 4uC in the dark. Stained nuclei were
Table 1. Colony-forming efficiency of CD133
+ cells versus
CD1332 population
a in SAOS2, MG63 and U2OS cell lines.
Nu colonies
% of formed
colonies
b Fold increase
c
SAOS2 CD133+ 5,561,8 5,761,9 4,260,9
CD1332 1,360,4 1,460,4 1
MG63 CD133+ 7,761,5 8,161,4 4,860,7
CD1332 1,660,5 1,760,6 1
U2OS CD133+ 6,861,7 7,361,8 4,560,9
CD1332 1,560,4 1,760,5 1
aResults are the mean6standard devition of three experiments from different
cases.
bRepresents the number of colonies with respect to the number of wells plated
in experiments.
cRatiobetweenthepercentageofcoloniesformedbyCD133+versusCD1332cells.
doi:10.1371/journal.pone.0003469.t001
Figure 6. Side population analysis. (A) Cytometric analyses of the side population. The CD133
+ fraction includes a small subset (0.97%),
expressing the characteristic profile of a side population at FACS. (B) ABCG2 expression in SAOS2 cell line, showing an evident positivity; the grey line
indicates the isotype control.
doi:10.1371/journal.pone.0003469.g006
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Mountain View, CA,USA), and the data analysed using a Mod-Fit
2.0 cell cycle analysis programme (Becton-Dickinson).
Growth analysis
After sorting by CD133, SAOS2, MG-63 and U2OS cells were
plated at a density of 8,0610
4 cells/well in 6-well plates. Every
twelve hours cells were harvested and re-suspended in PBS. An
aliquot of cell suspension was diluted with 0.4% trypan blue
(Sigma–Aldrich), pipetted onto a haemocytometer and counted
under a microscope at 2006magnification. Live cells excluded the
dye, whereas dead cells admitted the dye and consequently stained
intensely with trypan blue. The number of viable cells for each
experimental condition was counted and represented on a linear
graph. The doubling time (DT) was determined from the growth
curves or by using the formula:
DT~ t{t0 ðÞ log2= logN{logN0 ðÞ
where t and t0 were the times at which the cells were counted,
and N and N0 were the cell numbers at times t and t0, respectively
[32].
Figure 7. CD133 expression in adherent cells and floating spheres. (A) Immunohistochemical analyses on adherent cells and (B) floating
spheres showing the presence of CD133 antigen (arrows). (Original Magnification.6100); (C) Immunofluorescence analysis on SAOS-2 for CD133 PE,
cytoskeleton is stained with phalloidin-FITC, nucleus with DAPI (Original Magnification.6400); (D) Immunoflurescence analysis on SAOS-2 spheres for
CD133 PE after 24 hours in adhesion. (Original Magnification6200); (E) Confocal analyses on adherent cells and (F) floating spheres confirming the
presence of the CD133 antigen. (Original Magnification. 6400).
doi:10.1371/journal.pone.0003469.g007
CD133 in Solid Tumours
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In order to assay the different tumorigenic potential into two cell
fractions, CD133
+ and CD133
2 cells were plated in soft agar at a
density of 100, 500 or 1000 cells/well in 24 wells plates in
triplicate. Colo 38 melanoma cell line was used as positive control.
For the base layer, 2.4% agar stock solution was melted in a
microwave oven, cooled to 40 C in a water bath and then mixed
with culture medium to obtain a solution of 0.8% Agar in a-
MEM. 0.5 ml/well of this solution was added to 24-well plates.
For the top layer, the agar stock solution was diluted with culture
medium to obtain a solution of 0.3% agar in a-MEM. 0.5 ml/well
of the solution was gently mixed and aliquoted into the 24-well
plates. CD133
+, CD133
2 and wilde type SAOS-2, MG63 and
U2OS cells were successively plated and incubated for 21 days at
37uC in a humidified atmosphere of 5% CO2 in air and 50 ml a-
MEM. At the end of the incubation period, colonies were stained
with 150 ml/well of NBT (nitrobluetetraziolium) at the concen-
tration of 1 mg/2 ml in PBS, and counted using an inverted
microscope (Nikon TS 100, Nikon, Milan, Italy).
Immunofluorescence Staining
CD133
+ and CD133
2 cells cultured in 24-well plates were fixed
with a solution of 4% paraformaldehyde/0.2% Triton in PBS for
30 min at 4uC, washed in PBS, treated with PBS/5% milk for
60 min at room temperature and then stained with primary
antibodies at 4uC overnight. The primary antibodies used were
mouse anti-human CD133/2 PE conjugated (Miltenyi Biotec),
mouse anti-human Phalloidin FITC conjugated (AlexaFluor-
Invitrogen) incubated for 60 min at 4uC. The nuclei were stained
with DAPI. Cells were then washed twice as described above and
observed under the fluorescence microscope (Nikon TE 2000-S,
Milan, Italy). Isotypes and non-probed cells were used as controls.
Sphere Assays
Cells were plated at a density of 60,000 cells/well in 6-well ultra
low attachment plates (Corning Inc., Corning, NY, USA) in
DMEM/F12 cell medium, supplemented with 1% methylcellu-
lose, progesterone (10 nM), putrescine (50 mM), sodium selenite
(15 nM), transferrin (13 mg/ml), insulin (10 mg/ml; Sigma) and
human EGF (10 ng/ml) and human bFGF (10 ng/ml; Sigma)
[13]. Fresh aliquots of EGF and bFGF were added every other
day. After culture for 48–72 hours, spheres were visible at inverted
phase-contrast microscope (Nikon TS 100, Nikon).
Laser-scanning confocal microscopy
Cells grown in 24 well plates were fixed with 4% paraformal-
dehyde for 30 min at 4uC, washed in PBS, treated with PBS/5%
milk for 60 min at room temperature and then incubated with
primary antibodies at 4uC over night. The primary antibody was a
mouse anti-human CD133/1 Pure (Miltenyi Biotec); the second-
Figure 8. CD133 intracellular expression in adherent cells. (A) Figure performed at FACS showing intracellular expression of CD133 antigen in
SAOS-2, MG-63 and U2OS. (B) Figure showing at the Real time PCR the mRNA transcript expression in CD133
+ and CD133
2 cells. The levels are almost
identical as detected by in both CD133 positive and negative cells.
doi:10.1371/journal.pone.0003469.g008
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was incubated for 60 min at 4uC, and the DAPI, used to stain the
nucleus, was incubated for 7 minutes at room temperature. The
same procedure was performed on sarcospheres. All labelled cells
were stored at 4uC before images acquisition, using a Zeiss Laser-
scanning confocal microscope LSM 510 Meta (Zeiss- Oberkocken-
Germany). Images were captured at a resolution of 5126512
pixels. The appropriate argon laser fluorescence for visualization
of the CD133 was used with an excitation wavelength of 488 nm
and emission filter BP 505–530.
Immunohistochemistry
Immunoistochemistry for CD133 on SAOS2, MG63 and
U2OS cells was performed. Cells were plated at a density of
50,000 cells/well in 24 well plates, fixed with 3.5% paraformal-
dehyde for 10 min at 4uC, and washed in PBS. Primary antibody
used was mouse anti-human CD133/1 Pure (Miltenyi Biotec). For
secondary antibody and staining, the DAKO Cytomation En
Vision+System-HRP kit (AEC) was used according to the
manufacturer’s instructions. The nuclei were stained with
haematoxylin and the cells were observed under an inverted light
microscope. This procedure was also performed on sarcospheres.
RT-Real time PCR
Sequences for mRNAs from the nucleotide data bank (National
Center for Biotechnology Information, USA) were used to design
primer pairs for RT-PCR reactions (Primer Express, Applied
Biosystems, CA, USA). Primer sequences are available on request.
Appropriate regions of HPRT (Hypoxanthine-guanine phosphor-
ibosyltransferase) cDNA were used as controls. PCR cycles were
adjusted to have linear amplification for all the targets. Each RT-
PCR reaction was repeated at least 3 times. The Real Time PCR
assays were run on Opticon 4 machine (MJ, Research, Waltham,
MT, USA). Reactions were performed according to the manu-
facturer’s instructions by using SYBR green PCR Master mix.
Primer sequences were designed with Primer express software.
All the above described experiments were performed in
quadruplicates
Statistical analysis
Student t-test was used for statistical evaluation. Level of
significance was set at p,0.05.
Author Contributions
Conceived and designed the experiments: VT VD GP. Performed the
experiments: VT VD FDF GU CC. Analyzed the data: VT Rd ADR GP.
Contributed reagents/materials/analysis tools: GP ADR GP. Wrote the
paper: VT VD GP.
References
1. Klein MJ, Siegal GP (2006) Osteosarcoma: anatomic and histologic variants.
Am J Clin Pathol 125: 555–81.
2. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic
advances for pediatric osteosarcoma. Oncologist 9: 422–41. Review.
3. Kansara M, Thomas DM (2007) Molecular pathogenesis of osteosarcoma. DNA
Cell Biol 26: 1–18.
4. Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin
Biotechnol Oct;18(5): 460–6. Review.
5. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene
Sep 20;23(43): 7274–82. Review.
6. Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel
microvilli-specific polytopic membrane protein of the apical surface of epithelial
cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl
Acad Sci USA 94: 12425–30.
7. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. (1997) A novel five-
transmembrane hematopoietic stem cell antigen: isolation, characterization, and
molecular cloning. Blood 90: 5013–5021.
8. Fargeas CA, Corbeil D, Huttner WB (2003) AC133 antigen, CD133, prominin-
1, prominin-2, etc.: prominin family gene products in need of a rational
nomenclature. Stem Cells 21: 506–8.
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004)
Identification of human brain tumour initiating cells. Nature Nov 18;432(7015):
396–401.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007)
Identification and expansion of human colon-cancer-initiating cells. Nature Jan
4;445(7123): 111–5.
11. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:
1444–1450.
12. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al. (2007)
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumorigenic potential. Eur J Cancer 43: 935–46.
13. Gibbs CP, Kukekov VG, Reith JD, Reith DJ, Tchigrinova O, et al. (2005) Stem-
like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967–76.
14. Raile K, Ho ¨flich A, Kessler U, Yang Y, Pfuender M, et al. (1994) Human
osteosarcoma (U-2OS) cells express both insulin-like growth factor-I (IGF-I)
receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P)
receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the
IGF-I receptor. J Cell Physiol 159: 531–41.
15. Xu Z, Choudhary S, Voznesensky O, Mehrotra M, Woodard M, et al. (2006)
Overexpression of COX-2 in human osteosarcoma cells decreases proliferation
and increases apoptosis. Cancer Res Jul 1;66: 6657–64.
16. Takeuchi Y, Fukumoto Y, Matsumoto T (1995) Relationship between actions of
transforming growth factor (TGF)-beta and cell surface expression of its
receptors in clonal osteoblastic cells. J Cell Physiol 162: 315–321.
17. Pautke C, Schieker M, CSCher T, et al. (2004) Characterization of
osteosarcoma cell lines MG-63, Saos-2 and U-2OS in comparison to human
osteoblasts. Anticancer Res 24: 3743–8.
18. Jordan CT, Guzman ML, Noble M (2006) Cancer Stem cells. N Engl J Med
355: 1253–1261.
19. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation
and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor
cell properties. Cancer Res 65(13): 5506–11.
20. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65:
10946–51.
21. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007)
Identification of a subpopulation of cells with cancer stem cell properties in head
and neck squamous cell carcinoma. Proc Natl Acad Sci U S A Jan 16;104(3):
973–8.
22. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev
Cancer 5: 275–84.
23. Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC
(2006) Cancer stem cells - new and potentially important targets for the therapy
of oral squamous cell carcinoma. Oral Dis 12: 443–54.
24. Locke M, Heywood M, Fawell S, Mackenzie IC (2005) Retention of intrinsic
stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 65: 8944–50.
25. Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, et al. (2003)
Fbx15 Is a Novel Target of Oct3/4 but Is Dispensable for Embryonic Stem Cell
Self-Renewal and Mouse Development. Molecular and Cellular Biology 23:
2699–2708.
26. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, et al. (2007)
Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 7:
6.
27. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK (2005) A
distinct ‘‘side population’’ of cells in human tumor cells: implications for tumor
biology and therapy. Cell Cycle 4: 203–5.
28. Hadnagy A, Gaboury L, Bealieua R, Balickia D (2006) SP analysis may be used
to identify cancer stem cell populations. Exp Cell Res 312: 3701–3710.
29. Bunting KD (2002) Cells ABC Transporters as Phenotypic Markers and
Functional Regulators of stem cells. Stem Cells 20: 11–20.
30. Choi CH (2005) ABC transporters as multidrug resistance mechanism and the
development of chemosensitizers for their reversal. Cancer Cell Int 5: 30.
31. Goodell MA, Brose K, Paradis G, et al. (1996) Isolation and functional
properties of murine hematopoietic stem cells that are replicating in vivo. J Exp
Med 183: 1797–806.
32. Yoneda M, Chomyn A, Martinuzzi A, Hurko O, Attardi G (1992) Marked
replicative advantage of human mtDNA carrying a point mutation that causes
the MELAS encephalomyopathy. Proc Natl Acad Sci USA 89: 11164–11168.
CD133 in Solid Tumours
PLoS ONE | www.plosone.org 10 October 2008 | Volume 3 | Issue 10 | e3469